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Abstract
Multiple protein quality control systems operate to ensure that misfolded proteins are effi-
ciently cleared from the cell. While quality control systems that assess the folding status of
soluble domains have been extensively studied, transmembrane domain (TMD) quality con-
trol mechanisms are poorly understood. Here, we have used chimeras based on the type I
plasma membrane protein CD8 in which the endogenous TMD was substituted with trans-
membrane sequences derived from different polytopic membrane proteins as a mode to
investigate the quality control of unassembled TMDs along the secretory pathway. We find
that the three TMDs examined prevent trafficking of CD8 to the cell surface via potentially
distinct mechanisms. CD8 containing two distinct non-native transmembrane sequences
escape the ER and are subsequently retrieved from the Golgi, possibly via Rer1, leading
to ER localisation at steady state. A third chimera, containing an altered transmembrane
domain, was predominantly localised to the Golgi at steady state, indicating the existence
of an additional quality control checkpoint that identifies non-native transmembrane do-
mains that have escaped ER retention and retrieval. Preliminary experiments indicate that
protein retained by quality control mechanisms at the Golgi are targeted to lysosomes for
degradation.
Introduction
Between 20% and 30% of the proteome of eukaryotic organisms is predicted to be integral
membrane proteins [1]. These proteins are typically synthesised at the endoplasmic reticulum
(ER), where transmembrane domains (TMDs) are integrated into the lipid bilayer and cyto-
plasmic/luminal domains undergo the folding steps and post-translational modifications
necessary to achieve the native structure [2]. From the ER, correctly folded proteins are incor-
porated into transport vesicles for delivery to the cis-Golgi and subsequently to the trans-Golgi
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network (TGN), from where they are sorted to their site of function [3]. In contrast, proteins
that fail to attain the correct conformation are prevented from moving along the secretory
pathway by a series of quality control checkpoints, including those at the ER, Golgi apparatus
and plasma membrane [4–6].
The best studied quality control checkpoint is the ER system, which identifies non-native
features of proteins that have failed to fold correctly and retains them in the ER. Retained pro-
teins may undergo further rounds of folding, or be transferred to the ER-associated degrada-
tion (ERAD) machinery which initiates ubiqutination and movement of the misfolded protein
back across the ER membrane into the cytosol for degradation by the proteasome [7]. The
molecular mechanisms underlying the quality control of cytoplasmic and luminal domains at
the ER are relatively well understood and involve the recognition of non-native determinants,
such as exposed hydrophobic patches, by molecular chaperones [8, 9]. In addition to cyto-
plasmic and luminal domains, integral membrane proteins also contain a variable number of
hydrophobic TMDs composed of 18–25 amino acids that form α-helices which span the mem-
brane to integrate the protein into the bilayer. TMDs are not simply inert membrane anchors,
but typically possess specific properties that contribute to the structure, function and location
of the native protein [10, 11]. The intra- and intermolecular assembly of TMDs is a critical
step in the biogenesis of many membrane proteins [11–13]. However, relatively little is known
about how and where proteins containing TMDs which have failed to fold or assemble cor-
rectly are identified along the secretory pathway. A number of ER quality control factors have
been shown to contribute to the recognition and ERAD targeting of integral membrane pro-
teins possessing TMD defects, including the lectin calnexin [14–17], E3 ubiquitin ligases [18,
19], RHBDL4 [20] and UGGT [21]. Mechanistically, recognition of aberrant TMDs may be
mediated directly by the membrane spanning regions of these quality control proteins, as was
elegantly shown for the yeast E3 ligase Hrd1p [18]. Although the exact nature / structure of the
TMD defects they recognise are not clear, a common idea is that misfolding or misassembly of
TMDs causes exposure of non-native features such as polar residues or mismatched hydropho-
bic lengths that would normally be shielded from the bilayer in the native structure [13, 22,
23]. Indeed, charged or strongly polar intramembrane residues cause ER retention of unas-
sembled subunits of several oligomeric membrane proteins, and can also induce retention and
ERAD of reporter proteins [24–27]. However, some membrane proteins with unassembled
TMDs [28–30] or inferred TMD defects [31–33] are able to exit the ER. In some cases, unas-
sembled subunits of oligomeric membrane proteins that leave the ER may be retrieved by
Rer1, a sorting receptor localised to the cis-Golgi that recognises exposed polar residues in the
TMDs of cargo proteins and returns them to the ER [28, 30, 34, 35]. Rer1 has also recently
been implicated in the ER retention of misfolded membrane proteins in mammalian cells [14,
36], suggesting it may have a more general role in the identification of defective TMDs in the
early secretory pathway.
In addition to quality control at the ER, some non-native membrane proteins have been
shown to be retained in the Golgi of mammalian cells and targeted to lysosomes for degrada-
tion, suggesting additional quality control checkpoints in this compartment [31, 37]. Most
known substrates of the Golgi quality control pathway to date have been characterised in yeast,
where recognition is accompanied by sorting into intraluminal vesicles in multivesicular bod-
ies and degradation in the vacuole [6, 38, 39]. In yeast, the presence of polar residues within
TMDs is important for sorting of vacuolar proteins at the Golgi [40–42], and has also been
proposed to contribute to the selection of quality control substrates to be targeted to the vacu-
ole for degradation [40]. Likewise, in mammalian cells, introduction of two charged residues
into the TMD of hemagglutanin resulted in targeting to the lysosome for degradation, indicat-
ing TMDs that escape ER quality control (ERQC) are subject to quality control at the Golgi
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[35]. However, few mammalian Golgi quality control substrates have been characterised and it
is not known if misassembled or aberrant TMDs can be directly recognised in this organelle.
The objectives of this study were to investigate where and how unassembled TMDs are
identified within the secretory pathway of mammalian cells. Using chimeric reporters based
on the single spanning membrane protein CD8, we show that TMD sequences derived from
different polytopic membrane proteins prevent transport to the cell surface and cause ER loca-
lisation. ER localisation is achieved through a combination of retention and retrieval mecha-
nisms, and we provide evidence that Rer1 contributes to retrieval. Shortening one of these
TMD sequences allowed the chimera to escape from the ER, but resulted in Golgi localisation,
suggesting a second checkpoint at the Golgi may recognise non-native TMDs.
Materials and methods
Antibodies and reagents
α-CD8 and rabbit α-HA were obtained from Sigma, α-BAP31, α-Actin and α-tubulin from
AbCam, α-ERGIC53 from Alexis, mouse α-HA from Santa Cruz, α-EEA1 from Cell signalling
and α-GM130 from BD biosciences. IRDye 800 CW and IRDye 680 RD antibodies were from
LI-COR, and fluorescently conjugated secondary antibodies for microscopy were from Jack-
son Laboratories (Stratech Scientific). The inhibitors leupeptin (Enzo Life Sciences), pepstatin
A (Sigma), Z-LLF-CHO (PSII, Calbiochem), and cycloheximide (CHX, Sigma) were used at a
final concentration of 0.5 mM, 1 μg/ml, 10 μM, and 100 μg/ml respectively.
Constructs
CD8TMD

and CD8WT were generated as described previously [43]. CD8TMD23 was generated
using the deletion protocol from the Phusion Site-directed mutagenesis kit (Thermo Scientific).
CD8SERCA and CD8PMCA cDNAs [44] were provided by Dr J.M. East, University of Southampton.
These constructs contained TMD10 from rat SERCA and rabbit PMCA, and were cloned into the
pcDNA5.1/FRT/TO vector with a HA tag added at the C-terminus by PCR. It should be noted
that CD8WT and CD8TMD

differed from CD8PMCA and CD8SERCA in the 4 residues predicted to
be immediately adjacent to the TMD on the cytoplasmic face of the membrane (NHRN compared
with KRLK respectively; S1A Fig), although both sequences would be expected to ensure the same
topology according to the positive inside rule [45]. All further constructs were generated by site
directed mutagenesis. All sequences were verified by DNA sequencing (GATC Biotech).
Transfections
Stable HeLa TRex Flp-In cells expressing CD8 chimeras were generated by transfecting paren-
tal TRex HeLa cells (provided by Steven Taylor, University of Manchester) using Lipofecta-
mine LTX (Invitrogen) following manufacturer’s instructions. Transfected cells were selected
using 100 μg/ml hygromycin B (ForMedium) and 4 μg/ml blasticidin (InvivoGen). Once
established, cell lines were maintained in complete DMEM (DMEM (Sigma) supplemented
with 10% FBS, 2 mM L-glutamine and 1% non-essential amino acids) at 37˚C, 8% CO2. All
experiments were performed after inducing expression with 1 μg/ml tetracycline for 16–20
hours unless otherwise stated. For siRNA transfections, cells were seeded at 25,000 cells / well
in a 12 well dish. The following day, cells were transfected with INTERFERin (Polyplus Trans-
fection), using a final concentration of 20 nM siRNA duplex. Experiments were performed
48–72 hours post-transfection. Rer1 targeting siRNA oligo 1 sequence: 5’-UAUCAGUCCUGG
CUAGAC-3’; Rer1 siRNA oligo 2 sequence: 5’-UGCGAGUUACAGAAUGUCUGA-3’. Cal-
nexin siRNA sequence: 5’-UCAUCAUCGGUAUCGUCUU-3’
Transmembrane domain quality control at the ER and Golgi
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Quantitative PCR
RNA was extracted from siRNA treated cells 72 hours post-transfection using TRIzol (Invitro-
gen). 1μg RNA was converted to cDNA using the AMV first strand cDNA synthesis kit for
RT-PCR (Roche) and subsequently diluted at 3 5-fold dilutions. qPCR was carried out using
SYBR green mastermix (Eurogentec) and an Opticon qPCR thermal cycler (Genetic Research
Instrumentation). Rer1 transcript levels were normalised relative to GAPDH. Rer1 primers
were from QIAgen, GAPDH primers were Fwd: AAGGGCATCCTGGGCTACand Rev: GTGG
AGGAGTGGGTGTCG.
Microscopy
For colocalisation analysis, cells were induced to express the indicated CD8 chimeras overnight.
Subsequently cells were fixed in 3% formaldehyde (Sigma) in PBS (137 mM NaCl; 2.7 mM KCl;
10 mM Na2HPO4; 2 mM KH2PO4; pH 7.4) for 15 min at room temperature. Unreacted formal-
dehyde was quenched with glycine. Cells were permeabilised with 0.1% Triton X-100 for 4 min.
For selective permeabilisation (S2 Fig), cells were either permeabilised with 0.1% Triton X-100
for 4 min or with 40μg/ml digitonin for 4 min. CD8 chimeras and subcellular markers were
labelled with primary antibodies for 30–60 min followed by the appropriate fluorescently conju-
gated secondary antibody. Cells were mounted in ProLong Gold Antifade Reagent with DAPI
(Molecular Probes). For cell surface labelling, cells were pre-chilled for 20 min and labelled with
α-CD8 antibodies for 30 min, all on iced water. Subsequently, cells were washed in cool PBS,
fixed in formaldehyde and processed as above. For temperature block analysis, cells were incu-
bated in CO2-independent media at 15˚C or 37˚C for 3 hours prior to fixation and processing
as above. All images were captured using an Olympus BX-60 upright microscope with a 60X
1.40 N.A. PlanApo objective and a CoolSNAP EZ camera (Photometrics) using MetaMorph
software (MDS Analytical Technologies). Image montages were created in ImageJ (http://
rsbweb.nih.gov/ij/) and final figures collated in Illustrator CS5 (Adobe).
SDS-PAGE and immunoblotting
Prior to SDS-PAGE, samples were heated in SDS-PAGE sample buffer (30 mM Tris pH 7.6;
2% SDS; 5% glycerol; 0.01% bromophenol blue; 100 mM DTT). Samples were separated on
12% acrylamide gels after heating. For immunoblot analysis, proteins were transferred onto
nitrocellulose membrane (LI-COR) using a TE22 wet transfer tank (Hoefer). Immunoreactive
bands were detected with the ODYSSEY Sa infrared imaging system and quantified using
ODYSSEY Sa Infrared Imaging System Application Software Version 1.0.12 (LI-COR).
Pulse labelling and maturation
Cells were starved in DMEM lacking met / cys (GIBCO) for 30 min at 37˚C prior to labelling
in the presence of 22 μCi/ml [35S] met / cys EasyTag EXPRESS35S protein labelling mix (Per-
kinElmer) at 37˚C for 10 min. Subsequently, cells were washed in PBS and incubated in com-
plete DMEM supplemented with 10 mM non-radioactive met / cys for the indicated chase
time at 37˚C. Cells were then washed in PBS and lysates were prepared by solubilisation in
IP-Tx buffer (10 mM Tris-HCL pH 7.6, 140 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 1
mM PMSF) followed by centrifugation at 15,000 g for 10 min at 4˚C. Post-nuclear superna-
tants (PNS) were taken and incubated with α-HA antibody overnight at 4˚C, prior to the addi-
tion of protein A sepharose (Genscript) at 4˚C for a further 3 hours. Immuno-sepharose
complexes were washed 3 times in IP-Tx buffer before resuspension in reducing sample buffer
for analysis by SDS-PAGE and phosphorimaging.
Transmembrane domain quality control at the ER and Golgi
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Trypsinisation of cell surface proteins
Cells were induced to express the indicated CD8 chimeras overnight. Subsequently, cells were
either harvested directly in sample buffer (no trypsin) or incubated in 0.5% trypsin-EDTA solu-
tion (Sigma) at 37˚C for 3 min to detach cells before incubating on slush ice for 90 min. Subse-
quently, cells were treated with 0.5 mg/ml soybean trypsin inhibitor (SBTI) for 15 min, washed,
centrifuged and harvested in sample buffer for analysis by SDS-PAGE and immunoblotting.
Biotinylation of cell surface proteins
Cells were induced to express the indicated CD8 chimeras overnight. Subsequently, cells were
pre-chilled on ice and labelled with 0.5 mg/ml EZ-Link Sulfo-NHS-SS-biotin (Pierce Biotech-
nology) in PBS/CM (PBS + 0.9 mM CaCl2, 0.33 mM MgCl2) for 30 minutes with gentle rock-
ing. Cells were washed with PBS/CM, and unreacted biotin was quenched with 50 mM NH4Cl
in PBS/CM. Subsequently, cells were lysed in biotin lysis buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 5 mM EDTA, 1.25% TritonX-100, 0.25% SDS, 1 mM PMSF) followed by centrifugation
at low speed for 15 min. Post-nuclear supernatants were incubated with NeutrAvidin beads
(Thermo Scientific) for 2.5 h, washed 3 times in biotin lysis buffer and the resulting beads
resuspended in reducing sample buffer for analysis by SDS-PAGE and immunoblotting.
Cycloheximide chase analysis
Cells were induced to express the indicated CD8 chimeras overnight. Subsequently, cells were
incubated at 37˚C in complete DMEM containing 100 μg/ml cycloheximide to block further
protein synthesis. Where indicated, inhibitors were added to the media throughout the chase.
At the indicated time after the addition of CHX, cells were washed twice with PBS and lysed in
sample buffer. All samples were analysed by SDS-PAGE and immunoblotting.
Statistical analysis
Unpaired t-tests and one-way ANOVAs with Tukey’s multiple comparisons test were carried
out where indicated using GraphPad Prism 7.  indicates p< 0.05,  indicates p< 0.01.
Results
Diverse unassembled transmembrane domains cause ER localisation
We recently established a chimeric model protein for studying TMD quality control, in which
the endogenous TMD of the type I membrane protein CD8 was replaced with TMD 4 of a
4-pass membrane protein (proteolipid protein, PLP; [43]). We showed that although the extra-
cellular/luminal domain is folded, this chimera, termed CD8TMD

, is localised to the ER and
degraded via ERAD [43]. Thus when expressed in the absence of TMDs 1–3 of PLP, this TMD
sequence exposes signals that can be recognised by the ER quality control machinery. In order
to examine whether TMD sequences from other multi-spanning membrane proteins also
cause retention at the ER, we generated two further CD8 chimeras, in which the endogenous
TMD was replaced with TMD 10 from two Ca2+-ATPases, PMCA3 and SERCA1, herein
referred to as CD8PMCA and CD8SERCA respectively (Fig 1A). An HA epitope was fused to the
end of the cytoplasmic C-terminus. These TMDs were chosen as, in contrast to the sequence
present in CD8TMD

, they both possess a positive predicted ΔGapp for membrane insertion [46]
(Fig 1A), allowing us to investigate marginally hydrophobic TMDs. This is important as previ-
ous work suggests that such TMDs may fail to integrate stably into the bilayer in the absence of
partner TMDs, leading to their recognition by luminal ERQC [47, 48]. In addition, CD8PMCA
and CD8SERCA differ substantially from CD8TMD

in terms of their amino acid composition
Transmembrane domain quality control at the ER and Golgi
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and length, and thus represent diverse transmembrane spanning sequences for comparison of
quality control of unassembled TMDs.
Initially we examined the localisation of these constructs. In order to overcome potential
problems associated with variable expression levels obtained by transient transfection, we
Fig 1. Diverse unassembled TMDs mediate ER localisation. (A) Cartoon schematic of the domain structure of CD8α. The TMD amino acid
sequence and predicted ΔGapp for TMD membrane insertion of CD8WT, CD8TMD*, CD8PMCA and CD8SERCA are shown. (B) Cells expressing
CD8WT, CD8TMD*, CD8PMCA or CD8SERCA were fixed with formaldehyde, permeabilised with Triton X-100 and co-immunostained with
antibodies against BAP31 and the epitope tag HA. Cell nuclei were stained with DAPI (represented in blue in merged images). Scale bars
indicate 10 μm.
https://doi.org/10.1371/journal.pone.0173924.g001
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generated HeLa cell lines stably expressing these CD8 chimeras under a tetracycline-inducible
promoter. At steady state, CD8WT was present primarily at the cell surface and showed little
co-localisation with the ER-marker BAP31 (Fig 1B, top). In contrast, CD8TMD

displayed a
reticular staining pattern which overlapped with that of BAP31, indicating ER localisation (Fig
1B) as previously established [43]. Likewise, both CD8PMCA and CD8SERCA were observed in a
reticular pattern typical of the mammalian ER and exhibited a high degree of co-localisation
with BAP31 (Fig 1B), showing that these TMDs also caused localisation at the ER.
Given that the TMDs of CD8PMCA and CD8SERCA both had positive predicted ΔGapp values,
indicating unfavourable energetics for membrane insertion, it was important to examine
whether they were in fact membrane integrated. Marginally hydrophobic TMDs may fail to
integrate stably into the ER membrane and thus translocate fully into the ER lumen in the
absence of partner subunits [47, 48]. To this end, the accessibility of the extracellular/ER lumi-
nal CD8 domain and the HA epitope at the C-terminus of these chimeras was examined after
selective permeabilisation. In cells treated with digitonin the membranes of the ER remained
intact and the luminal lectin calreticulin was not accessible for antibody labelling (S2A Fig,
bottom). Under these conditions, the HA epitope of CD8TMD

and CD8PMCA could be clearly
detected (S2B and S2C Fig, bottom), indicating the C-termini of these proteins were correctly
located on the cytoplasmic side of the ER. In contrast, labelling with the anti-CD8 antibody
was only apparent after ER membranes had been permeabilised with Triton X-100 and was
not detected in digitonin-permeabilised cells (S2B and S2C Fig), suggesting that the N-termi-
nal domains of these proteins were located within the ER lumen. On the basis of these results,
we conclude that CD8TMD

and CD8PMCA are integrated into the ER membrane with the cor-
rect topology. For CD8SERCA however, neither the N- nor C-terminal domains were accessible
to antibody labelling in digitonin-treated cells, but were revealed upon permeabilisation of ER
membranes with Triton-X 100 (S2D Fig). This indicates that both the N- and C-termini of
CD8SERCA were located inside the ER lumen. Hence, this chimera may not be stably integrated
into the ER membrane, but translocated fully into the ER lumen, as observed for other proteins
containing marginally hydrophobic TMDs [47, 48]. Alkaline extraction experiments demon-
strated that a large proportion of CD8SERCA could be removed from cellular membranes upon
treatment with sodium carbonate pH 11 (S3C Fig), confirming that this chimera is not mem-
brane integrated. This is in contrast to CD8TMD

[43] and CD8PMCA (S3B Fig), which were
almost completely resistant to carbonate extraction, remaining stably associated with the
membrane fraction. Thus, whilst chimeras containing the three different non-native TMD
sequences were localised at the ER, this may be achieved via distinct mechanisms.
Retention and retrieval mechanisms contribute to ER localisation of
unassembled transmembrane domains
The observation that CD8TMD

and CD8PMCA are membrane integrated and localised to the
ER suggests that both of these TMD segments expose specific signals within the lipid bilayer
that result in recognition by ERQC mechanisms. Such signals may be masked in the context of
the full length proteins, since the TMDs from multispanning membrane proteins typically
interact and/or assemble with neighbouring TMDs in their native conformation, as has been
proposed for PLP [49]. Since little is known about TMD-based QC, we next examined the
mechanisms underlying ER localisation of these chimeras. Whilst some unassembled or mis-
folded proteins are retained statically in the ER, others exit the ER and undergo retrieval from
the Golgi [14, 28, 29, 36]. Our previous work showed that a proportion of CD8TMD

receives
Golgi post-translational modifications, suggesting that it is able to partially escape from the ER
to later stages of the secretory pathway [43]. Thus, CD8TMD

was initially synthesised as a 25
Transmembrane domain quality control at the ER and Golgi
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kDa species (Fig 2A, lane 1), respesenting the unmodified precursor (termed ‘u’) following
pulse-labelling with [35S] amino acids [43, 50–52]. Over time, a proportion of the precursor
was converted to several higher molecular weight forms (Fig 2A, lanes 3–7): two closely mi-
grating bands of around 27 kDa representing intermediate O-glycoforms (termed ‘i’) previ-
ously shown to be generated in the cis-Golgi; and 2–3 species of approximately 30 kDa
observed after 15 minutes of chase, representing more mature O-glycoforms (termed ‘m’) that
are produced in the trans-Golgi network [43, 51, 52]. Consistent with the pulse-chase analysis,
CD8TMD

was predominantly observed in the unmodified and intermediate forms at steady
state, with a small but detectable amount of the ‘m’ glycoforms (Fig 2B lane 2). In contrast,
CD8WT was observed almost entirely in the ‘m’ form (Fig 2B lane 1), consistent with its pro-
gression through the secretory pathway and localisation to the cell surface (Fig 1B). Like
CD8TMD

, CD8PMCA was also observed as a mixture of the unmodified precursor and the inter-
mediate glycoforms at steady state (Fig 2B lane 3), showing that a proportion of this chimera
also escapes the ER and reaches the Golgi apparatus to undergo O-glycosylation. Although the
pattern of CD8TMD

and CD8PMCA glycoforms were comparable, their steady state expression
level of CD8PMCA appeared to be considerably lower than that of CD8TMD

(Fig 2B, compare
lanes 2 and 3). Since the expression vectors for the different chimeras are stably integrated into
the same genomic locus in each cell line, the differences in intracellular levels of the proteins at
steady state most likely reflect differences in the rates at which they are degraded rather than
differences in transcription or translation efficiency.
Since CD8TMD

and CD8PMCA were predominantly localised to the ER at steady state (Fig
1B), these results indicate that chimeras which exit the ER are subsequently retrieved from the
Golgi. In order to determine if this was the case, we examined the effect of reduced tempera-
ture on the subcellular distribution of the chimeras. Growth of cells at 15˚C inhibits exit of
proteins from the ER-Golgi intermediate compartment (ERGIC) in both retrograde and anter-
ograde directions [53–56]. Entry of proteins from the ER continues however, and therefore
proteins that cycle between the ER and Golgi accumulate in the ERGIC at 15˚C [53]. When
cells were incubated for 3 hours at 15˚C, the localisation of ERGIC53 was altered from the
large perinuclear stacks observed at 37˚C (Fig 2C–2E, top panels), to smaller, more numerous
compartments with a more disperse distribution (Fig 2C–2E, bottom panels), consistent with
accumulation of ERGIC53 in ERGIC compartments [53, 57]. At 37˚C, a proportion of both
CD8TMD

and CD8PMCA co-localised with ERGIC53 (Fig 2C and 2D, top panels). After 3 hours
at 15˚C however, a marked redistribution of CD8TMD

and CD8PMCA occurred, with a substan-
tially greater proportion of each chimera being concentrated in ERGIC53-positive compart-
ments (Fig 2C and 2D, bottom panels). We considered the possibility that accumulation of
CD8TMD

and CD8PMCA

in the ERGIC might be due to inhibition of anterograde transport
of newly synthesised protein from the ERGIC to the cis-Golgi. However, CD8WT was not
observed in ERGIC53-positive compartments after 3 hours at 15˚C (Fig 2E, bottom panel).
This suggests that the accumulation of CD8TMD

and CD8PMCA in the ERGIC at 15˚C was not
solely due to inhibition of anterograde transport from the ERGIC (which would also cause
accumulation of CD8WT), but also reflects inhibition of retrograde transport that returns
CD8TMD

and CD8PMCA, but not CD8WT, from the ERGIC to the ER. Thus, on the basis of
these results, we conclude that retrieval mechanisms contribute to the ER localisation of CD8
containing non-native TMDs.
Rer1 contributes to the retrieval of CD8TMD*
We next addressed the mechanism that mediates retrieval of CD8 TMD chimeras from the
Golgi. Rer1 is a membrane protein that cycles between the ER and Golgi and has been
Transmembrane domain quality control at the ER and Golgi
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Fig 2. CD8TMD* and CD8PMCA are retrieved from the Golgi. (A) Cells expressing CD8TMD* were pulse labelled with [35S] met/
cys for 10 minutes and chased for up to 90 minutes as indicated. Samples were immunoprecipitated with antibodies against HA,
Transmembrane domain quality control at the ER and Golgi
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implicated in the retrieval of proteins from the Golgi to the ER via recognition of exposed
polar residues within TMDs. Helical wheel projections of the TMDs of CD8TMD

and
CD8PMCA indicated that the polar and charged residues are spatially clustered in both proteins,
forming potential Rer1 interaction motifs [30]. This is particularly true of CD8TMD

, where 5
polar residues were predicted to be grouped on one side of the helix (Fig 3A). In order to deter-
mine whether Rer1 contributes to the ER localisation of CD8TMD

, we examined the effect of
siRNA-mediated knockdown of Rer1. Rer1 depletion (~57% reduction in Rer1 mRNA levels,
Fig 3B; > 80% reduction in levels of exogenously expressed Rer1-V5 protein, S4A Fig) caused
a marked change in the distribution of CD8TMD

, such that it appeared predominantly in
punctate structures that were distributed throughout the cell (Fig 3C, compare top and bot-
tom). A similar effect was observed using a second independent siRNA oligonucleotide target-
ing Rer1 (S4B Fig). The puncta induced by Rer1 siRNA did not colocalise with ERGIC53 (Fig
3C, bottom, white inset box), indicating that they do not correspond to the ERGIC or cis-
Golgi. Rer1 knockdown has recently been shown to cause a misfolded membrane protein
usually degraded by ERAD to accumulate in lysosomes [36], and we therefore examined
whether these puncta represented CD8TMD

en route to lysosomes. Indeed, some co-localisa-
tion between CD8TMD

-containing puncta and the endosomal marker EEA1 was observed
upon Rer1 depletion (Fig 3D, bottom), but not in scrambled siRNA-treated cells (Fig 3D, top).
Notably, only a proportion of the CD8TMD

positive puncta were also positive for EEA1, con-
sistent with CD8TMD

transiting through endosomes in Rer1 depleted cells. The appearance of
CD8TMD

in EEA1 positive structures upon Rer1 knockdown indicates that protein which
escapes retrieval from the Golgi is ultimately sorted to lysosomes for degradation. A small
increase in the proportion of CD8TMD

was seen in the Golgi modified ‘i’ and ‘m’ forms in
Rer1 depleted cells than in control cells (Fig 3E), consistent with a greater proportion of
CD8TMD

reaching the Golgi in the absence of Rer1-mediated retrieval. Lysosomal protease
inhibitors stabilised the higher molecular weight ‘m’ glycoform generated in the trans-Golgi
network [43], and this effect was most apparent in Rer1 depleted cells (Fig 3E and 3F). Hence
following treatment with leupeptin and pepstatin, the ratio of Golgi-modified ‘i’ and ‘m’ glyco-
forms relative to the ER retained ‘u’ form was significanly (P = 0.0337) higher in Rer1 depleted
cells than in cells treated with scrambled siRNA (Fig 3F), suggesting a greater proportion of
CD8TMD

escaped the ER in the absence of Rer1. Together these results provide evidence that
Rer1-mediated retrieval contributes to maintaining ER localisation of CD8TMD

, and that
CD8TMD

which escapes retrieval is at least in part targeted to lysosomes for degradation.
A Golgi quality control checkpoint for transmembrane domains
We next investigated which features of the transmembrane sequence in CD8TMD

contributed
to its ER localisation. At 30 residues, the transmembrane sequence in CD8TMD

is likely to be
longer than the thickness of the membrane, a so-called positive mismatch [58]. We therefore
examined the effect of shortening the TMD of CD8TMD

by removing the seven C-terminal
residues of the TMD to create CD8TMD23, and in doing so also removed three of the polar
amino acids that contributed to the putative Rer1 recognition motif (Fig 4A and 4B). These
changes markedly altered the subcellular distribution of the chimera, and in contrast to the
perinuclear and reticular localisation of CD8TMD

, CD8TMD23 was predominantly localised to a
separated by SDS-PAGE and analysed by phosphorimaging. (B) Whole cell lysates of cells expressing CD8WT, CD8TMD* or
CD8PMCA were separated by SDS-PAGE and analysed by immunoblotting with antibodies against HA and tubulin. (C-E) Cells
expressing (C) CD8TMD*, (D) CD8PMCA or (E) CD8WT were incubated at 15˚C or 37˚C for 3 hours prior fixation. Cells were co-
immunostained with antibodies against ERGIC53 and the epitope tag HA. Scale bars indicate 10 μm.
https://doi.org/10.1371/journal.pone.0173924.g002
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Fig 3. CD8TMD* retrieval from the Golgi is mediated by Rer1. (A) Helical wheel projections for the transmembrane domains of
CD8TMD* and CD8PMCA. Numbering starts from the N-terminus of the predicted TMD. (B) Rer1 mRNA levels were determined by
Transmembrane domain quality control at the ER and Golgi
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ribbon-like structure typical of the mammalian Golgi apparatus (Fig 4C, middle panels). Rela-
tively little CD8TMD23 appeared to be ER retained, as judged by co-localisation with BAP31
(Fig 4C). A much higher degree of co-localisation with the cis-Golgi marker GM130 was
observed (Fig 4D), suggesting that more CD8TMD23 escaped from ER retention and / or
retrieval mechanisms. Consistent with this observation, a significantly greater proportion of
CD8TMD23 was observed in higher molecular weight Golgi modified ‘i’ and ‘m’ glycoforms
than CD8TMD

at steady state (Fig 5A and 5B; P = 0.0109). To examine ER-to-Golgi transport
of CD8TMD23 more directly, we followed the acquisition of Golgi modifications using pulse-
chase radiolabelling as described previously. Like CD8TMD

(Fig 2A), CD8TMD23 was predomi-
nantly synthesised as the ‘u’ form with a smaller amount of the glycosylated intermediate ‘i’
during the 10 minute pulse (Fig 5C, lane 1). The mature glycoform ‘m’ appeared after 15–30
minutes of chase (Fig 5C lane 4) as observed for CD8TMD

(Fig 2A). However, in contrast to
CD8TMD

(Fig 2A), essentially all of the CD8TMD23 was modified to the ‘i’ and ‘m’ forms during
the timecourse of the experiment (Fig 5C). As observed for CD8WT (Fig 5D), very little, if any,
CD8TMD23 remained in the ‘u’ precursor form after 60 minutes of chase (Fig 5C, lane 6). The
lack of modification of CD8TMD

(Fig 2A) was not due to its luminal domain being resistant to
O-glycosylation, since treatment of cells with brefeldin A to redistribute Golgi glycosidase
enzymes to the ER, rapidly converted all of the CD8TMD

to the higher molecular weight ‘i’ and
‘m’ forms [43]. These data suggest that like CD8WT, the great majority of CD8TMD23 escaped
from the ER and reached the Golgi within 70 minutes (10 minutes pulse plus 60 minutes
chase).
Thus, we conclude that the seven residues in the C-terminal portion of the TMD were pri-
marily responsible for the ER retention / retrieval of CD8TMD

. The effect of deleting these resi-
dues could reflect disruption of the putative Rer1 recognition motif and / or the effect of
shortening the TMD and thus reducing a hydrophobic mismatch. However, it is noteworthy
that the localisation of CD8TMD23 was distinct from that of CD8TMD

upon treatment with
Rer1 siRNA (compare Figs 4D and 3C respectively). This observation indicates that the two
TMDs are handled differently upon arrival at the Golgi. Hence, whilst CD8TMD

appeared to
be targeted to the endo/lysosomal system upon Rer1 siRNA, CD8TMD23 was predominantly
retained at the Golgi.
Although CD8TMD23 was efficiently transported to the Golgi, little was seen at the plasma
membrane of permeabilised cells. Cell surface labelling of intact cells with an antibody against
the extracellular domain of CD8 revealed only faint cell surface labelling in cells expressing
CD8TMD23 compared to that seen in cells expressing CD8WT (Fig 5E). Similarly, treatment
with membrane-impermeable Sulfo-NHS-SS-Biotin to selectively label cell surface protein
resulted in modification of only a small amount of CD8TMD23 compared to CD8WT (Fig 5F,
compare lanes 8 and 4). Whilst treatment of intact of cells with trypsin resulted in proteolysis
of the majority of CD8WT (Fig 5G, lane 2), CD8TMD23 was largely protected from externally
added protease (Fig 5G, lane 4). Together, these experiments show that relatively little
CD8TMD23 was located at the cell surface. Thus, even though CD8TMD23 was able to evade ER
qPCR 72h post transfection with scrambled or Rer1 siRNA and normalised relative to GAPDH mRNA levels. (C and D) Cells
expressing CD8TMD* were transfected with scrambled siRNA or siRNA targeting Rer1 as indicated. 72 hours subsequently, cells were
fixed and co-immunostained with antibodies against (C) ERGIC53 and HA or (D) EEA1 and HA. Cell nuclei were stained with DAPI.
Scale bars indicate 10 μm. (E) Cell expressing CD8TMD* were transfected with scrambled siRNA or siRNA targeting Rer1 for 72 hours.
Immediately prior to harvesting, cells were incubated with leupeptin and pepstatin A (L/P) for 5 hours or left uninhibited. Whole cell
lysates were separated by SDS-PAGE and analysed by immunoblotting with antibodies against HA. (F) Signal intensities from high
molecular weight ‘i’ and ‘m’ glycoforms expressed as a ratio to the unprocessed ‘u’ glycoform. Scrambled siRNA vs RER1 siRNA + L/P,
p = 0.0015; Rer1 siRNA vs Rer1 siRNA + L/P, p = 0.0267; scrambled siRNA + L/P vs Rer1 siRNA + L/P, p = 0.0337; one way ANOVA
with Tukey’s multiple comparisons test. Data represents mean ±S.E.M. from 3 independent experiments.
https://doi.org/10.1371/journal.pone.0173924.g003
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retention and / or retrieval mechanisms, it was subsequently retained at the Golgi apparatus
(Fig 4D). These findings are important as they suggest the existence of a quality control check-
point at the Golgi which is able to recognise features of the non-native TMD sequence present
in CD8TMD23.
Little is known about Golgi quality control mechanisms, particularly in mammalian cells,
and therefore, we next examined the fate of CD8TMD23. The stability of CD8TMD23 was analysed
Fig 4. CD8TMD23 is a substrate from Golgi quality control. (A) Cartoon schematic of the domain structure of CD8α. The amino acid
compositions and predicted ΔGapp for TMD membrane insertion of CD8TMD* and CD8TMD23 are shown. (B) Helical wheel projection for the
transmembrane domain of CD8TMD23. Numbering starts from the N-terminus of the predicted TMD. (C and D) Cells expressing CD8TMD* or
CD8TMD23 were fixed and co-immunostained with antibodies against (C) BAP31 or (D) GM130 as well as the epitope tag HA in all cases. Cell
nuclei were stained with DAPI. Scale bars indicate 10 μm.
https://doi.org/10.1371/journal.pone.0173924.g004
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by cycloheximide chase assays in which cells expressing CD8TMD23 were treated with cyclohex-
imide to inhibit further protein synthesis, and then ‘chased’ for up to 120 minutes in the pres-
ence of cycloheximide. Cells were harvested at different times following the addition of
cycloheximide, and the amount of CD8TMD23 remaining at each time point was determined by
SDS-PAGE and immunoblotting. In contrast to CD8WT, the levels of which remained rela-
tively constant, CD8TMD23 was rapidly lost during the 120 minute chase (Fig 6A), suggesting
that CD8TMD23 was unstable. Inclusion of the proteasome inhibitor Z-LLF-CHO (PSII) in the
chase media substantially slowed the loss of CD8TMD23, with twice as much protein remaining
at each time point (Fig 6A and 6B). Since it is not clear how protein would be targeted to pro-
teasomes directly from the Golgi, this observation suggests that some CD8TMD23 is recognised
Fig 5. CD8TMD23 is predominantly retained in the Golgi. (A) Whole cell lysates of cells expressing CD8WT, CD8TMD* or CD8TMD23 were
separated by SDS-PAGE and analysed by immunoblotting with antibodies against HA. (B) Ratios of signal intensities of intermediate ‘i’ and
mature ‘m’ to unprocessed ‘u’ glycoforms of CD8TMD* or CD8TMD23 at steady state (n = 3). P = 0.0109, unpaired t-test. (C & D) Cells expressing
(C) CD8TMD23 or (D) CD8WT were pulse labelled with [35S] met/cys for 10 minutes and chased for up to 90 minutes as indicated. Samples were
immunoprecipitated with antibodies against HA, separated by SDS-PAGE and analysed by phosphorimaging. (E) In parallel, cells expressing
CD8WT or CD8TMD23 were chilled on ice and labelled with antibodies against the extracellular domain of CD8 prior to fixation in formaldehyde. Note
that pictures were taken in parallel with equal exposure times. Scale bars indicate 10 μm. (F) Cells expressing CD8WT or CD8TMD23 were chilled on
iced water and labelled with biotin prior to cell lysis. Total cell lysates samples were taken and the remaining cell lysate incubated with neutravidin
to isolate biotinylated (cell surface) protein. Total ‘T’ and biotinylated ‘B’ samples were separated by SDS-PAGE and analysed by immunoblotting
with antibodies against HA, tubulin and Hsp70. (G) Cells expressing CD8WT or CD8TMD23 were incubated on ice and treated with trypsin. Subsequently
cells were washed and whole cell lysates separated by SDS-PAGE and analysed by immunoblotting with antibodies against HA and actin.
https://doi.org/10.1371/journal.pone.0173924.g005
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at the ER and degraded via ERAD, as previously demonstrated for CD8TMD

[43]. However, in
contrast to CD8TMD

, proteasome inhibition did not lead to accumulation of the ‘u’ precursor
in the ER (Fig 6A), indicating that any CD8TMD23 not degraded by ERAD was instead trans-
ported to the Golgi and underwent post translational modification to the ‘i’ and ‘m’ forms (Fig
6A). Treatment with the lysosomal protease inhibitors leupeptin and pepstatin A also reduced
CD8TMD23 degradation (Fig 6A and 6B), suggesting that CD8TMD23 retained at the Golgi is tar-
geted to lysosomes for degradation.
Together, these results suggest a model whereby proteins with non-native TMDs are able to
exit the ER and travel to the Golgi apparatus, from where they can either be returned to the ER
via retrograde transport involving Rer1, or are retained via an unknown mechanism and ulti-
mately routed to lysosomes for degradation (Fig 7).
Discussion
The role of TMD-based signals in the quality control of misfolded membrane proteins in
mammalian cells is poorly understood. This has remained a difficult question to address since
few model proteins that contain aberrant transmembrane segments but folded luminal and
Fig 6. CD8TMD23 is degraded by proteasomes and lysosomes. (A) Cells expressing CD8WT or CD8TMD23
were treated with cycloheximide (CHX) to prevent further protein synthesis. Whole cell lysates were harvested
at the indicated chase time, separated by SDS-PAGE and analysed by immunoblotting with antibodies
against HA and the loading control actin. Where indicated, cells expressing CD8TMD23 were treated with
leupeptin and pepstatin A (LP) or PSII concurrently with CHX. (B) Signal intensities from (A) were quantified,
normalised relative to the loading control and expressed as a percentage of the protein level at the start of the
chase. Data represents mean ±S.E.M. from 3 independent experiments.
https://doi.org/10.1371/journal.pone.0173924.g006
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cytoplasmic domains have been characterised. In this study, we have used TMD chimeras
based on CD8 to provide a simple model system to study how misassembled TMDs are identi-
fied and handled in the secretory pathway. Our results suggest that non-native TMDs are rec-
ognised by multiple checkpoints in the secretory pathway (Fig 7). At the level of the ER, we
found that both retention and retrieval facilitate ER localisation of CD8 chimeras containing
non-native TMDs, whilst additional mechanism(s) at the Golgi retain proteins that escape ER
retention/retrieval.
Both CD8TMD

and CD8PMCA were localised to the ER, and since substitution of the endog-
enous TMD of CD8 does not prevent folding of the ER luminal / extracellular domain ([43]
and refs therein) or integration into the ER membrane, we conclude that specific features of
the non-native TMD sequences prevent anterograde trafficking of these chimeras to the cell
surface. The chimeras are degraded via a proteasome-dependent pathway [43], suggesting that
the ERAD machinery recognises signals embedded within the lipid bilayer to promote degra-
dation of proteins containing non-native TMDs (Fig 7, step 1). The properties of the two exog-
enous TMD sequences in CD8TMD

and CD8PMCA are quite distinct in terms of their amino
acid composition, hydrophobicity and length (Fig 1A, S1A Fig), showing that diverse TMD
sequences have the potential to mediate ER retention and degradation. However, both se-
quences do contain a number of polar residues that could act as determinants for recognition
by transmembrane proteins that monitor TMD assembly. Quality control factors that could
potentially contribute to ER retention of CD8TMD

and CD8PMCA include calnexin, which has
been implicated in the retention of several proteins containing misassembled TMDs [14–17]
and ERAD E3 ubiquitin ligases such as Hrd1, which in S. cerevisiae recognise aberrant TMDs
directly [18, 19]. An additional possibility to the recognition of specific sequence motifs is that
partitioning into particular membrane environments such as lipid microdomains or lipid
droplets due to the physiochemical properties of the TMD sequences contributes to quality
control of proteins containing aberrant TMDs [24]. In this regard it is noteworthy that bioin-
formatic and experimental studies have provided evidence that TMD length is an important
Fig 7. Transmembrane domain quality control at the ER and Golgi. A model for the handling of proteins
containing misassembled transmembrane domains (red ovals). (1) Proteins containing misassembled
transmembrane domains may be retained in the ER and degraded via ERAD. (2) A proportion of these
proteins may cycle between the ER and Golgi. Golgi-to-ER retrieval is at least in part mediated by Rer1 (blue
oval). (3) Proteins that are not retrieved to the ER may be retained by Golgi quality control machinery. (4)
Proteins that escape ER retrieval are degraded in lysosomes. Some protein may traffic to the cell surface. It is
not clear whether trafficking to the plasma membrane is a prerequisite for targeting to lysosomes, or whether
proteins containing aberrant TMDs can be directly targeted to the endo/lysosomal system from the Golgi.
https://doi.org/10.1371/journal.pone.0173924.g007
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determinant of membrane protein localisation, with longer more hydrophobic TMDs being
located at the cell surface and shorter more hydrophilic TMDs favouring ER/Golgi localisation
[10]. A discrepancy between the length of the TMD and the thickness of the membrane, such
is the case for CD8TMD

, is predicted to be energetically unfavourable and may lead to tilting
within the membrane in order to minimise the energetic cost of hydrating hydrophobic
regions [59]. Whether such alterations in the lipid bilayer contribute to the quality control of
proteins possessing aberrant TMDs is an important and as yet unanswered question.
Despite their predominant ER localisation and degradation via ERAD, neither CD8TMD

nor CD8PMCA were stringently retained in the ER. A considerable pool of each protein escaped
to the Golgi apparatus and underwent retrieval via retrograde transport through the ERGIC
(Fig 7, step 2). This is interesting as it indicates that retention of non-native TMDs by ER qual-
ity control may be relatively inefficient, and depend upon retrieval from the Golgi to maintain
ER localisation and promote ERAD. Indeed, knockdown of Rer1, which has been previously
been implicated in the retrieval of ER resident and misfolded / misassembled membrane pro-
teins [14, 30, 36, 60, 61], increased escape of CD8TMD

from the ER and lead to its accumula-
tion in endo/lysosomal compartments, suggesting that lack of retrieval from the Golgi results
in delivery to lysosomes (Fig 7, step 4). Previous studies have identified polar residues within
TMDs as being critical to recognition by Rer1 [28, 30, 34], and both CD8TMD

and CD8PMCA
contain clusters of polar residues that could potentially form Rer1 binding motifs (Fig 3A).
Deletion of the seven residues at the cytoplasmic C-terminal end of the TMD of CD8TMD

,
which contained three polar residues, caused the resulting protein CD8TMD23 to localise to the
Golgi. The simplest interpretation of this observation is that the deletion disrupted the putative
Rer1 recognition motif, and thus prevented retrieval from the Golgi to the ER, leading to accu-
mulation in the Golgi. However, deletion of these residues also shortened the length of the pre-
dicted TMD in CD8TMD23 and therefore the difference in length may also contribute to the
distinct localisation of CD8TMD

and CD8TMD23. Indeed, shortening the TMD also appeared to
reduce static retention of CD8TMD23 in the ER, since essentially all pulse-labelled CD8TMD23
received Golgi modifications within 60 min, in contrast to only around 50% of CD8TMD

[43].
In either case, the observation that CD8TMD23 accumulates in the Golgi suggests that a second
TMD-based checkpoint operates to retain CD8TMD23 at this compartment (Fig 7, step 3).
While CD8TMD23 appeared to localise predominantly to the Golgi at steady state, this chi-
mera was degraded by a combination of both proteasome and lysosome dependent pathways.
Proteasome inhibition lead to accumulation of the higher molecular weight glycoforms but
not the unmodified precursor, suggesting that CD8TMD23 not degraded by ERAD exits the ER
and moves to the Golgi as observed for several other misfolded proteins [62, 63]. This would
be consistent with a model whereby static retention of CD8TMD23 in the ER is inefficient, with
any protein not degraded by ERAD being exported to the Golgi apparatus. From the Golgi,
CD8TMD23 could be delivered to lysosomes for degradation (Fig 7, step 4) directly as has been
observed in yeast for proteins containing exposed polar residues [40, 42]. It is also possible that
trafficking of CD8TMD23 from the Golgi to the lysosome may occur via the cell surface (Fig 7,
step 4). In this scenario, CD8TMD23 would move from the Golgi to the cell surface, from where
it would be incorporated into endocytic vesicles and subsequently sorted for deliver to lyso-
somes. Further work will be aimed at elucidating the contribution of endocytosis to the han-
dling of proteins containing unassembled TMDs.
Interestingly, the distribution of CD8TMD23, which was localised to Golgi stacks, differed
from that of CD8TMD

upon Rer1 siRNA treatment, which appeared in punctate structures.
The reasons for this have not been defined, but may reflect different handling of CD8TMD

and
CD8TMD23 in the Golgi. It is conceivable that CD8TMD

is more efficiently targeted to the endo/
lysosomal system than CD8TMD23, and therefore localised with greater frequency in punctate
Transmembrane domain quality control at the ER and Golgi
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structures. Indeed, polar residues within TMDs have previously been implicated in protein
sorting from the Golgi to vacuoles in S. cerevisiae [37, 40]. Whether polar residues are similarly
crucial to TMD recognition in the Golgi of mammalian cells requires further examination,
and future work will be focussed on defining quality control at the Golgi.
Supporting information
S1 Fig. Cartoon diagram showing the transmembrane domains sequences (bold, in boxes)
from the constructs used in this study.
(TIF)
S2 Fig. Antibody labelling indicates CD8SERCA does not integrate into ER membranes. (A)
HeLa cells were fixed and permeabilised with Triton X-100 or digitonin, then co-immunos-
tained with antibodies against a cytoplasmic epitope of the ER membrane protein BAP31 and
the luminal ER protein calreticulin (CRT). Cell nuclei were stained with DAPI (represented in
blue in merged images). Scale bars represent 10 μm. (B) Cells expressing CD8TMD

were fixed
and permeabilised with Triton X-100 or digitonin. Cells were co-immunostained with anti-
bodies against the luminal domain of CD8 or the cytosolic HA tag. (C) Cells expressing
CD8PMCA were treated as in (B). (D) Cells expressing CD8SERCA were treated as in (B).
(TIF)
S3 Fig. Carbonate extraction of CD8TMD23, CD8PMCA and CD8SERCA. Cells were induced to
express (A) CD8TMD23, (B) CD8PMCA or (C) CD8SERCA. Lysates were subjected to alkaline
extraction as described previously (Briant et al, 2015, J Cell Sci 128(22):4112–25). Samples
of the input postnuclear supernatant (PNS), cytosol, total membranes, carbonate extracted
material (CO3 supernatant) and carbonate resistant material (CO3 pellet) were analysed by
reducing SDS-PAGE and immunoblotting with antibodies to CD8 (anti-HA), an ER luminal
protein (BiP) and an integral ER membrane protein (BAP31). The efficiency of the carbonate
extraction is shown by the enrichment of BiP in the CO3 supernatant and BAP31 in the CO3
pellet.
(TIF)
S4 Fig. Rer1 mediates CD8TMD

retrieval from the Golgi. (A) HEK293 cells stably expressing
V5-tagged Rer1 were left untreated, treated with siRNA targeting Rer1 or treated with a con-
trol siRNA targeting calnexin. 72h post transfection, whole cell lysates were taken and knock-
down efficiency assessed by immunoblotting with antibodies against the V5 tag and Rer1. (B)
HeLa cells expressing CD8TMD

were treated with scrambled siRNA or second siRNA targeting
Rer1. The distribution of CD8TMD was subsequently detected with α-HA antibodies. Scale
bars indicate 10 μm.
(TIF)
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